{
    "clinical_study": {
        "@rank": "13198", 
        "arm_group": [
            {
                "arm_group_label": "BBI608 in combination with cetuximab", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BBI608 in combination with panitumumab", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BBI608 in combination with capecitabine", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open label study of BBI608 in combination with cetuximab, panitumumab or\n      capecitabine in patients with advanced colorectal cancer."
        }, 
        "brief_title": "A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer", 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is an open label, multi-center, Phase II study of BBI608 administered in combination\n      with either cetuximab, or panitumumab, or capecitabine. A cycle will consist of daily and\n      continuous oral administration of BBI608 for four weeks in combination with either\n      cetuximab, or panitumumab, or capecitabine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed written informed consent must be obtained and documented according to\n             International Conference on Harmonization (ICH), Good Clinical Practice(GCP), the\n             local regulatory requirements, and permission to use private health information in\n             accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior\n             to study-specific screening procedures.\n\n          -  A histologically or cytologically confirmed colorectal cancer that is metastatic,\n             unresectable, or recurrent.\n\n          -  Patients must have received at least 2 regimens containing\n             5-Fluorouracil,oxaliplatin, or irinotecan.\n\n          -  Patients to be enrolled in the Cetuximab or Panitumumab combination arms must have\n             colorectal cancer which is K-Ras wild-type.\n\n          -  \u2265 18 years of age.\n\n          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST\n             1.1).\n\n          -  Karnofsky performance Status \u2265 70%\n\n          -  Male or female patients of child-producing potential must agree to use contraception\n             or avoidance of pregnancy measures during the study and for 30 days after the last\n             BBI608 dose.\n\n          -  Females of childbearing potential must have a negative serum pregnancy test.\n\n          -  Aspartate transaminase (AST) and alanine transaminase (ALT) \u22641.5 \u00d7 upper limit of\n             normal(ULN), or \u2264 2.5 \u00d7 ULN with metastatic liver disease.\n\n          -  Hemoglobin (Hgb) \u2265 10 g/dl.\n\n          -  Total bilirubin \u2264 1.5 \u00d7 ULN.\n\n          -  Creatinine \u2264 1.5 \u00d7 ULN or creatinine clearance > 60 mL/min/1.73 m^2 for patients with\n             creatinine levels above institutional normal.\n\n          -  Absolute neutrophil count \u2265 1.5 x 10^9/L.\n\n          -  Platelets \u2265 100 x 10^9/L.\n\n          -  Life expectancy \u2265 3 months.\n\n        Exclusion Criteria:\n\n          -  Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents\n             within four weeks of first dose with the exception for a single dose radiation up to\n             8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days\n             before beginning the administration of BBI608.\n\n          -  Surgery within 4 weeks prior to first dose.\n\n          -  Any known symptomatic brain metastases requiring steroids. Patients with treated\n             brain metastases must be stable for 4 weeks after completion of that treatment, with\n             image documentation required. Patients must have no clinical symptoms from brain\n             metastases and must be either off steroids or on a stable dose of steroids for at\n             least 2 weeks prior to protocol enrollment. Patients with known leptomeningeal\n             metastases are excluded, even if treated.\n\n          -  Pregnant or breastfeeding\n\n          -  Significant gastrointestinal disorder(s), in the opinion of the Principal\n             Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small\n             intestine resection)\n\n          -  Unable or unwilling to swallow BBI608 capsules daily.\n\n          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active\n             infection, clinically significant non-healing or healing wounds, symptomatic\n             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant\n             pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled\n             infection or psychiatric illness/social situations that would limit compliance with\n             study requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776307", 
            "org_study_id": "BBI608-224"
        }, 
        "intervention": [
            {
                "arm_group_label": "BBI608 in combination with cetuximab", 
                "description": "BBI608 is administered at 500 mg po bid continuously and cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.", 
                "intervention_name": "BBI608 and cetuximab", 
                "intervention_type": "Drug", 
                "other_name": "Erbitux"
            }, 
            {
                "arm_group_label": "BBI608 in combination with panitumumab", 
                "description": "BBI608 is administered at 500 mg po bid continuously and panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.", 
                "intervention_name": "BBI608 and panitumumab", 
                "intervention_type": "Drug", 
                "other_name": "Vectibix"
            }, 
            {
                "arm_group_label": "BBI608 in combination with capecitabine", 
                "description": "BBI608 is administered at 500 mg po bid continuously and capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.", 
                "intervention_name": "BBI608 and capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "BBI608", 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Sanaa.Tahiri@osumc.edu", 
                    "last_name": "Sanaa Tahiri", 
                    "phone": "614-293-5894"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "The Ohio State University Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Taios Bekaii-Saab, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Melissa.kirsch@uphs.upenn.edu", 
                    "last_name": "Melissa Kirsch, RN", 
                    "phone": "215-349-5785"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Abramson Cancer Center of the University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Peter O'Dwyer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jkueber@ghs.org", 
                    "last_name": "Jan Kueber, RN", 
                    "phone": "864-455-3600"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }, 
                    "name": "Institute for Translational Oncology Research, Greenville Hospital System"
                }, 
                "investigator": {
                    "last_name": "William J. Edenfield, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer", 
        "overall_official": {
            "affiliation": "Institute for Translational Oncology Research, Greenville Hospital System", 
            "last_name": "William J. Edenfield, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of Disease Control Rate, defined as the proportion of patients with a documented complete response, partial response and stable disease based on RECIST, in patients with advanced colorectal cancer given BBI608 in combination with cetuximab, panitumumab or capecitabine", 
            "measure": "Disease Control Rate", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776307"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessment of Overall Survival in patients with advanced colorectal cancer given BBI608 in combination with cetuximab, panitumumab or capecitabine", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of death,  assessed up to 100 months"
            }, 
            {
                "description": "Assessment of Progression Free Survival in patients with advanced colorectal cancer given BBI608 in combination with cetuximab, panitumumab or capecitabine by performing tumor assessments every 8 weeks.", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of first documented progression or death, whichever comes  first, assessed up to 100 months"
            }, 
            {
                "description": "Assessment of safety of BBI608 given in combination with cetuximab, panitumumab or capecitabine to patients with advanced colorectal cancer by reporting of adverse events and serious adverse events", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Adverse events will be assessed at baseline, while the participant is taking BBI608, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months."
            }, 
            {
                "description": "Observe the area under the plasma concentration versus time curve of BBI608 in combination with cetuximab, BBI608 in combination with panitumumab, and BBI608 in combination with capecitabine", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "On Day 5 and Day 26 in the cetuximab combination arm; on Day 8 and 22 in the panitumumab combination arm; and on Day 8 and 21 in the capecitabine combination arm"
            }, 
            {
                "description": "Pharmacodynamic assessments to analyze biomarkers in tumor tissues will be performed in patients when tumor biopsy with a minimally invasive procedure is deemed possible by Investigator.", 
                "measure": "Pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "At baseline and at 4 hours after administration of BBI608 morning dose on Day 8"
            }
        ], 
        "source": "Boston Biomedical, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston Biomedical, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}